Publications by authors named "Neil N Senzer"

Claim this Profile
E
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Stephen Mf Jamieson, Peter Tsai, Maria K Kondratyev, Pratha Budhani, Arthur Liu, Neil N Senzer

JCI Insight· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Stephen Mf Jamieson, Peter Tsai, Maria K Kondratyev, Pratha Budhani, Arthur Liu, Neil N Senzer

JCI Insight· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
Howard L Kaufman, Thomas Amatruda, Tony Reid, Rene Gonzalez, John Glaspy, Neil N Senzer

J Immunother Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Devalingam Mahalingam, John J Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven Weitman, Neil N Senzer

Cancer Chemother Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
Lipika Goyal, Jeffrey G Supko, Jordan Berlin, Lawrence S Blaszkowsky, Amanda Carpenter, Neil N Senzer

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Charles M Rudin, John T Poirier, Neil N Senzer, Joseph Stephenson, David Loesch

Clin Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
Lecia V Sequist, Scott Gettinger, Neil N Senzer, Renato G Martins, Pasi A Jänne

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
David Loesch, F Anthony Greco, Neil N Senzer, Howard A Burris, John D Hainsworth

J Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Neil N Senzer, Howard L Kaufman, Thomas Amatruda, Mike Nemunaitis, Tony Reid

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
Robert M Eager, C Casey Cunningham, Neil N Senzer, Joe Stephenson, Stephen P Anthony

BMC Cancer· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging technologies for the genomic analysis of cancer.
John Nemunaitis, Neil N Senzer

F1000 Biol Rep· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemo-inducible gene therapy.
James J Mezhir, Hank Schmidt, Bakhtiar Yamini, Neil N Senzer, Mitchell C Posner

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Wells A Messersmith, Daniel A Laheru, Neil N Senzer, Ross C Donehower, Paula Grouleff

Clin Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Denis Soulieres, Neil N Senzer, Everett E Vokes, Manuel Hidalgo, Sanjiv S Agarwala

J Clin Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis